[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-chronic-inflammatory-demyelinating-polyneuropathy-cidp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-chronic-inflammatory-demyelinating-polyneuropathy-cidp":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100338251","phase-4-two-dose-levels-of-privigen-in-pediatric-cidp-100338251",false,"NCT03684018","Two Dose Levels of Privigen in Pediatric CIDP","Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP","Inclusion Criteria:\n\n* \\- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.\n\nExclusion Criteria:\n\n* \\- Absence of CIDP symptoms\n* -History or family history of inherited neuropathy\n* -Diagnosed developmental delay or regression\n* -History of thrombotic episode\n* -Known or suspected hypersensitivity to Privigen\n* -Known allergic or other severe reactions to blood products\n* -Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study\n* -Pregnant or breastfeeding mother\"","ALL","2 Years","17 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment",[27],"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","RECRUITING","2026-05-28",{"date":31,"type":32},"2026-06-01","ACTUAL",{"date":34,"type":32},"2019-02-28",{"date":36,"type":21},"2029-12-20",{"name":38,"class":39},"CSL Behring","INDUSTRY",9]